
News|Articles|October 7, 2026
Could CAR T Cells Be Reprogrammed After Infusion to Target Cancer Again?
In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
Advertisement
Advertisement
CAR T-cell therapy equips a patient’s T cells to recognize a specific tumor target, but that fixed recognition can become a limitation when cancer cells express different antigens or lose the target the therapy was designed to attack. A preclinical platform developed at City of Hope explores whether engineered T cells could be redirected after infusion—allowing clinicians to broaden tumor recognition without manufacturing an entirely new CAR T-cell product.
Related to this article

A transplant pharmacist looks at what azacitidine plus venetoclax’s event-free survival advantage over intensive chemotherapy means for induction selection, and why it doesn’t yet replace 7+3 or CPX-351.

In the phase 3 REGAL trial, galinpepimut-S reached a median overall survival of 24.0 months, compared with 14.7 months for best available treatment, in patients in second or later remission.

Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.

With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.

Higher doses of injectable semaglutide have been shown to cause greater weight loss than standard doses with a similar safety profile.

Early germline BRCA testing identifies patients with metastatic pancreatic adenocarcinoma who can be considered for olaparib maintenance if their disease has not progressed after at least 16 weeks of first-line platinum chemotherapy.

In every practice setting, pharmacists can meet vaccine hesitancy with evidence, effective communication, and vetted resources that move patients toward “yes.”
Advertisement
Advertisement
